article thumbnail

Requirements to Conduct First-in-Human (FIH) Clinical Trials for Biopharmaceuticals

ProRelix Research

The transition of a drug, medical device, or biopharmaceutical from the laboratory bench to bedside involves a long series of steps starting from drug discovery, computational chemistry, in vitro and […] The post Requirements to Conduct First-in-Human (FIH) Clinical Trials for Biopharmaceuticals appeared first on ProRelix Research.

article thumbnail

The Data-Driven Future of Drug Development

DrugBank

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug Repurposing: A New Life for Old Drugs

DrugBank

These include matching molecular signatures, virtual screening, and analyzing large datasets from health records and clinical trials. Despite the rise of open-source models, access to valuable data, like clinical trials, remains limited. Research infrastructure also presents hurdles.

Drugs 98
article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. For example, in the screening stage of a project we are trying to find initial starting points for optimisation by our medicinal and computational chemistry colleagues.

article thumbnail

How the AI revolution can accelerate early drug discovery

Drug Target Review

How AI/ML technology has accelerated drug discovery Although AI for drug discovery (AIDD) can be viewed as being in the initial phases of development and acceptance, compounds discovered using AIDD platforms are already entering clinical trials. Matthew subsequently put his computational chemistry skills to use in the defence sector.

Drugs 105
article thumbnail

Sygnature Discovery accelerates global growth with major North American acquisition

Sygnature Discovery

Founded in 2011, NuChem Sciences delivers expert integrated and standalone discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology.

article thumbnail

Accelerating Innovation, Deepening Integration | Viva Biotech Online Investor Day Review

The Pharma Data

As well as continuously upgrading and optimizing existing 9 major technology platforms, Viva has also invested heavily in the fields of Cryo-EM, Computational Chemistry/Biology, etc. Dr. Xueheng Cheng, CTO of Viva Biotech, introduced the ASMS technology platform.